Children Meningitis Vaccine

The Children Meningitis Vaccine is a highly effective product from AIM Persistence Biopharmaceutical Co., Ltd. As a manufacturer with R&D capabilities, our vaccine is a quadrivalent meningococcal vaccine, providing protection against four serotypes with a single dose, effectively addressing complex infection scenarios.

Meningitis is a respiratory disease to which children are particularly susceptible. The incidence rate is higher in children under five years old, with the highest incidence in infants under one year old, followed by adolescents and the elderly.

The Importance of Vaccination

The EPI of many countries around the world stipulates that teenagers need to receive the quadrivalent meningococcal vaccine.

Meningococcal disease poses a serious threat to life and health, especially among children, who are the most vulnerable group. Among newborn survivors, the risk of neurological sequelae is as high as 30%-50%, with hearing loss being the most common complication. Both the disease itself and its aftermath can have severe consequences for those affected.

However, by promptly arranging vaccinations in high-risk areas before the peak season, effective prevention can be achieved.

Product Advantages

Multiple Serotypes: Compared to ordinary meningococcal vaccines, which may only protect against one serotype, AIM Persistence's Children Meningitis Vaccine is a quadrivalent vaccine, protecting against meningococcal disease caused by four dominant serotypes: A, C, Y, and W135, providing more comprehensive protection.

High Seroconversion Rate: The vaccine has a seroconversion rate of >96% for all four meningococcal serotypes (A, C, Y, and W135).

Long Shelf Life: Our Xin'er Cong® series is the only meningococcal vaccine product with a 36-month shelf life.

Low Residual Rate: We do not add antibiotics or any preservatives during the production process, ensuring safe ingredients.